Display options
Cite
Silverstein SC, Rabadan R. How many neutrophils are enough (redux, redux)?. J Clin Invest. 2012;122(8):2776-9doi: 10.1172/JCI63939.
Silverstein, S. C., & Rabadan, R. (2012). How many neutrophils are enough (redux, redux)?. The Journal of clinical investigation, 122(8), 2776-9. https://doi.org/10.1172/JCI63939
Silverstein, Samuel C, and Rabadan, Raul. "How many neutrophils are enough (redux, redux)?." The Journal of clinical investigation vol. 122,8 (2012): 2776-9. doi: https://doi.org/10.1172/JCI63939
Silverstein SC, Rabadan R. How many neutrophils are enough (redux, redux)?. J Clin Invest. 2012 Aug;122(8):2776-9. doi: 10.1172/JCI63939. Epub 2012 Jul 23. PMID: 22820286; PMCID: PMC3533502.
Copy Download .nbib Format: NLM
Share it on

J Clin Invest. 2012 Aug;122(8):2776-9. doi: 10.1172/JCI63939. Epub 2012 Jul 23.

How many neutrophils are enough (redux, redux)?.

The Journal of clinical investigation

Samuel C Silverstein, Raul Rabadan

PMID: 22820286 PMCID: PMC3533502 DOI: 10.1172/JCI63939

Abstract

Many chemotherapeutic regimens produce neutropenia, which predisposes to microbial infection. However, not all neutropenic individuals develop infections, so the ability to predict this outcome would be a powerful clinical tool. In this issue of the JCI, Malka et al. describe a dynamic system model of neutrophil bactericidal activity that confirms and extends the concept of critical neutrophil concentration. The authors demonstrate that when the neutrophil concentration approaches the critical concentration, bacterial populations in contact with them exhibit bistability. Their experimental findings raise the intriguing possibility of greater variability in bactericidal activity of neutrophils from healthy adults than heretofore recognized; their model predicts that this could have life-and-death consequences.

References

  1. PLoS One. 2010 May 05;5(5):e10010 - PubMed
  2. PLoS Pathog. 2009 Oct;5(10):e1000639 - PubMed
  3. J Thromb Haemost. 2008 Mar;6(3):415-20 - PubMed
  4. J Clin Invest. 1987 Dec;80(6):1550-60 - PubMed
  5. J Anat. 1980 Jan;130(Pt 1):113-20 - PubMed
  6. J Immunol. 1996 May 15;156(10):3986-92 - PubMed
  7. Am J Cancer Res. 2012;2(2):204-13 - PubMed
  8. J Immunol. 2002 Jan 15;168(2):816-24 - PubMed
  9. J Exp Med. 1924 Jan 31;39(2):219-44 - PubMed
  10. FASEB J. 2008 Sep;22(9):3111-9 - PubMed
  11. Lancet. 1998 Jun 13;351(9118):1752-3 - PubMed
  12. Support Care Cancer. 2010 May;18(5):529-41 - PubMed
  13. Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8289-94 - PubMed
  14. Ann Intern Med. 1966 Feb;64(2):328-40 - PubMed
  15. J Immunol. 2009 Sep 1;183(5):3496-504 - PubMed
  16. Arch Intern Med. 1969 Jun;123(6):722-3 - PubMed
  17. J Exp Med. 2004 Sep 6;200(5):613-22 - PubMed
  18. Am J Physiol Lung Cell Mol Physiol. 2009 Feb;296(2):L198-209 - PubMed
  19. J Clin Invest. 2012 Aug;122(8):3002-11 - PubMed
  20. J Exp Med. 1969 Jun 1;129(6):1275-90 - PubMed
  21. Blood. 1986 Apr;67(4):1023-30 - PubMed
  22. Immunology. 1979 Jun;37(2):453-65 - PubMed
  23. Pediatr Res. 1996 May;39(5):835-42 - PubMed
  24. Cancer. 2004 Jan 15;100(2):228-37 - PubMed
  25. Circ Res. 2009 Jul 31;105(3):223-30 - PubMed
  26. Blood. 1998 Nov 1;92(9):3007-17 - PubMed
  27. J Cell Biol. 1984 Jul;99(1 Pt 1):336-9 - PubMed
  28. Blood. 1998 May 15;91(10):3962-6 - PubMed
  29. J Immunol. 2008 Oct 15;181(8):5183-8 - PubMed
  30. J Exp Med. 1959 Jul 1;110(1):27-48 - PubMed
  31. J Exp Med. 2010 Jan 18;207(1):223-35 - PubMed

Publication Types

Grant support